Lisa Licitra

List of Publications by Citations

50 papers	1,942 citations	14 h-index	44 g-index
56 ext. papers	2,856 ext. citations	6.7 avg, IF	4.04 L-index

#	Paper	IF	Citations
50	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. *Lancet, The*, **2019**, 394, 1915-1928	40	839
49	Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. *Oral Oncology*, **2018**, 81, 45-51	4.4	372
48	Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Oncology, The*, **2017**, 18, 323-335	21.7	133
47	Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. *Frontiers in Oncology*, **2017**, 7, 72	5.3	86
46	Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data. *Oncologist*, **2017**, 22, 1056-1066	5.7	80
45	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. *Therapeutic Advances in Medical Oncology*, **2018**, 10, 1758835918762094	5.4	74
44	Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus. *Lancet Oncology, The*, **2020**, 21, e350-e359	21.7	62
43	International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV. *Head and Neck*, **2019**, 41, 1725-1737	4.2	36
42	Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker. *BioMed Research International*, **2019**, 2019, 9056417	3	28
41	Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. *Cancer Treatment Reviews*, **2018**, 65, 78-86	14.4	24
40	Treatment challenges in and outside a network setting: Head and neck cancers. *European Journal of Surgical Oncology*, **2019**, 45, 40-45	3.6	21
39	Multivariable model for predicting acute oral mucositis during combined IMRT and chemotherapy for locally advanced nasopharyngeal cancer patients. *Oral Oncology*, **2018**, 86, 266-272	4.4	17
38	Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. *Cancers*, **2020**, 12,	6.6	15
37	Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. *Oral Oncology*, **2017**, 69, 33-37	4.4	14
36	Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. *Oral Oncology*, **2018**, 82, 144-151	4.4	11
35	Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer. *Oral Oncology*, **2019**, 95, 106-114	4.4	11
34	Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. *Laryngoscope*, **2020**, 130, 857-865	3.6	10

33	Failure of Further Validation for Survival Nomograms in Oropharyngeal Cancer: Issues and Challenges. *International Journal of Radiation Oncology Biology Physics*, **2018**, 100, 1217-1221	4	9
32	Quality of Care Indicators for Head and Neck Cancers: The Experience of the European Project RARECAREnet. *Frontiers in Oncology*, **2019**, 9, 837	5.3	8
31	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. *European Journal of Cancer*, **2020**, 136, 35-42	7.5	8
30	A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. *Oral Oncology*, **2019**, 90, 94-101	4.4	7
29	Low skeletal muscle mass as predictor of postoperative complications and decreased overall survival in locally advanced head and neck squamous cell carcinoma: the role of ultrasound of rectus femoris muscle. *European Archives of Oto-Rhino-Laryngology*, **2020**, 277, 3489-3502	3.5	7
28	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. *European Journal of Cancer*, **2018**, 93, 89-98	7.5	7
27	Nasopharyngeal cancer in non-endemic areas: Impact of treatment intensity within a large retrospective multicentre cohort. *European Journal of Cancer*, **2021**, 159, 194-204	7.5	6
26	Gene Expression Clustering and Selected Head and Neck Cancer Gene Signatures Highlight Risk Probability Differences in Oral Premalignant Lesions. *Cells*, **2020**, 9,	7.9	6
25	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. *European Journal of Cancer*, **2021**, 157, 250-258	7.5	6
24	Predictors of Patient-Reported Dysphagia Following IMRT Plus Chemotherapy in Oropharyngeal Cancer. *Dysphagia*, **2019**, 34, 52-62	3.7	5
23	PD-1 immunotherapy for recurrent or metastatic HNSCC. *Lancet, The*, **2019**, 394, 1882-1884	40	5
22	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. *Head and Neck*, **2019**, 41, 1895-1902	4.2	5
21	Phase III Randomized Study of Induction Chemotherapy Followed by Definitive Radiotherapy + Cetuximab Versus Chemoradiotherapy in Squamous Cell Carcinoma of Head and Neck: The INTERCEPTOR-GONO Study (NCT00999700). *Oncology*, **2020**, 98, 763-770	3.6	4
20	Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial. *Oral Oncology*, **2019**, 97, 82-91	4.4	3
19	A randomized, double-blind, placebo controlled, phase II study to evaluate the efficacy of ginseng in reducing fatigue in patients treated for head and neck cancer. *Journal of Cancer Research and Clinical Oncology*, **2020**, 146, 2479-2487	4.9	3
18	A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. *Cancers*, **2021**, 13,	6.6	3
17	Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. *Radiotherapy and Oncology*, **2021**, 164, 1-5	5.3	3
16	The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation. *Oral Oncology*, **2021**, 114, 105128	4.4	2

15	Intratumoral Cellular Heterogeneity: Implications for Drug Resistance in Patients with Non-Small Cell Lung Cancer. *Cancers*, **2021**, 13,	6.6	2
14	History of Extensive Disease Small Cell Lung Cancer Treatment: Time to Raise the Bar? A Review of the Literature. *Cancers*, **2021**, 13,	6.6	2
13	The important role of cisplatin in the treatment of HPV-positive oropharyngeal cancer assessed by real-world data analysis. *Oral Oncology*, **2021**, 121, 105454	4.4	2
12	Metabolism and Immune Modulation in Patients with Solid Tumors: Systematic Review of Preclinical and Clinical Evidence. *Cancers*, **2020**, 12,	6.6	1
11	Cost-effectiveness of Molecular Profile Patient Selection for First-line Treatment of Recurrent/Metastatic Head and Neck Cancer. *Clinical Therapeutics*, **2019**, 41, 2517-2528.e28	3.5	1
10	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. *European Journal of Cancer*, **2021**, 158, 17-26	7.5	1
9	Prognostic role of pre-treatment magnetic resonance imaging (MRI)-based radiomic analysis in effectively cured head and neck squamous cell carcinoma (HNSCC) patients. *Acta Oncologica*, **2021**, 60, 1192-1200	3.2	1
8	In Reply to Fakhry et al. *International Journal of Radiation Oncology Biology Physics*, **2018**, 102, 670-671	4	1
7	An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma.. *JCO Precision Oncology*, **2021**, 5, 1526-1527	3.6	1
6	Angiogenesis inhibition in lung cancer: emerging novel strategies. *Current Opinion in Oncology*, **2022**, 34, 107-114	4.2	0
5	Next generation platinum salt in nasopharygeal carcinoma. *Lancet Oncology, The*, **2021**, 22, 577-578	21.7	
4	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy **2020**, 15, e0232639		
3	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy **2020**, 15, e0232639		
2	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy **2020**, 15, e0232639		
1	Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy **2020**, 15, e0232639		